Myeloma bone disease

Pathophysiology and management

Rebecca Silbermann, G. David Roodman

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Multiple myeloma bone disease is marked by severe dysfunction of both bone formation and resorption and serves as a model for understanding the regulation of osteoblasts (OBL) and osteoclasts (OCL) in cancer. Myeloma bone lesions are purely osteolytic and are associated with severe and debilitating bone pain, pathologic fractures, hypercalcemia, and spinal cord compression, as well as increased mortality. Interactions within the bone marrow microenvironment in myeloma are responsible for the abnormal bone remodeling in myeloma bone disease. Myeloma cells drive bone destruction that increases tumor growth, directly stimulates the OCL formation, and induces cells in the marrow microenvironment to produce factors that drive OCL formation and suppress OBL formation. Factors produced by marrow stromal cells and OCL promote tumor growth through direct action on myeloma cells and by increasing angiogenesis. Current therapies targeting MMBD focus on preventing osteoclastic bone destruction; however regulators of OBL inhibition in MMBD have also been identified, and targeted agents with a potential anabolic effect in MMBD are under investigation. This review will discuss the mechanisms responsible for MMBD and therapeutic approaches currently in use and in development for the management of MMBD.

Original languageEnglish
Pages (from-to)59-69
Number of pages11
JournalJournal of Bone Oncology
Volume2
Issue number2
DOIs
StatePublished - Jun 2013

Fingerprint

Bone Diseases
Osteoclasts
Disease Management
Osteoblasts
Bone and Bones
Bone Marrow
Anabolic Agents
Neoplasms
Spontaneous Fractures
Spinal Cord Compression
Bone Remodeling
Hypercalcemia
Bone Resorption
Stromal Cells
Growth
Multiple Myeloma
Osteogenesis
Pain
Mortality
Therapeutics

Keywords

  • Angiogenesis
  • Bone marrow microenvironment
  • Myeloma
  • Myeloma bone disease
  • Osteoblast
  • Osteoclast

ASJC Scopus subject areas

  • Oncology

Cite this

Myeloma bone disease : Pathophysiology and management. / Silbermann, Rebecca; Roodman, G. David.

In: Journal of Bone Oncology, Vol. 2, No. 2, 06.2013, p. 59-69.

Research output: Contribution to journalArticle

@article{69103f197abf4deb83cf5d5753cbe6dc,
title = "Myeloma bone disease: Pathophysiology and management",
abstract = "Multiple myeloma bone disease is marked by severe dysfunction of both bone formation and resorption and serves as a model for understanding the regulation of osteoblasts (OBL) and osteoclasts (OCL) in cancer. Myeloma bone lesions are purely osteolytic and are associated with severe and debilitating bone pain, pathologic fractures, hypercalcemia, and spinal cord compression, as well as increased mortality. Interactions within the bone marrow microenvironment in myeloma are responsible for the abnormal bone remodeling in myeloma bone disease. Myeloma cells drive bone destruction that increases tumor growth, directly stimulates the OCL formation, and induces cells in the marrow microenvironment to produce factors that drive OCL formation and suppress OBL formation. Factors produced by marrow stromal cells and OCL promote tumor growth through direct action on myeloma cells and by increasing angiogenesis. Current therapies targeting MMBD focus on preventing osteoclastic bone destruction; however regulators of OBL inhibition in MMBD have also been identified, and targeted agents with a potential anabolic effect in MMBD are under investigation. This review will discuss the mechanisms responsible for MMBD and therapeutic approaches currently in use and in development for the management of MMBD.",
keywords = "Angiogenesis, Bone marrow microenvironment, Myeloma, Myeloma bone disease, Osteoblast, Osteoclast",
author = "Rebecca Silbermann and Roodman, {G. David}",
year = "2013",
month = "6",
doi = "10.1016/j.jbo.2013.04.001",
language = "English",
volume = "2",
pages = "59--69",
journal = "Journal of Bone Oncology",
issn = "2212-1374",
publisher = "Elsevier GmbH",
number = "2",

}

TY - JOUR

T1 - Myeloma bone disease

T2 - Pathophysiology and management

AU - Silbermann, Rebecca

AU - Roodman, G. David

PY - 2013/6

Y1 - 2013/6

N2 - Multiple myeloma bone disease is marked by severe dysfunction of both bone formation and resorption and serves as a model for understanding the regulation of osteoblasts (OBL) and osteoclasts (OCL) in cancer. Myeloma bone lesions are purely osteolytic and are associated with severe and debilitating bone pain, pathologic fractures, hypercalcemia, and spinal cord compression, as well as increased mortality. Interactions within the bone marrow microenvironment in myeloma are responsible for the abnormal bone remodeling in myeloma bone disease. Myeloma cells drive bone destruction that increases tumor growth, directly stimulates the OCL formation, and induces cells in the marrow microenvironment to produce factors that drive OCL formation and suppress OBL formation. Factors produced by marrow stromal cells and OCL promote tumor growth through direct action on myeloma cells and by increasing angiogenesis. Current therapies targeting MMBD focus on preventing osteoclastic bone destruction; however regulators of OBL inhibition in MMBD have also been identified, and targeted agents with a potential anabolic effect in MMBD are under investigation. This review will discuss the mechanisms responsible for MMBD and therapeutic approaches currently in use and in development for the management of MMBD.

AB - Multiple myeloma bone disease is marked by severe dysfunction of both bone formation and resorption and serves as a model for understanding the regulation of osteoblasts (OBL) and osteoclasts (OCL) in cancer. Myeloma bone lesions are purely osteolytic and are associated with severe and debilitating bone pain, pathologic fractures, hypercalcemia, and spinal cord compression, as well as increased mortality. Interactions within the bone marrow microenvironment in myeloma are responsible for the abnormal bone remodeling in myeloma bone disease. Myeloma cells drive bone destruction that increases tumor growth, directly stimulates the OCL formation, and induces cells in the marrow microenvironment to produce factors that drive OCL formation and suppress OBL formation. Factors produced by marrow stromal cells and OCL promote tumor growth through direct action on myeloma cells and by increasing angiogenesis. Current therapies targeting MMBD focus on preventing osteoclastic bone destruction; however regulators of OBL inhibition in MMBD have also been identified, and targeted agents with a potential anabolic effect in MMBD are under investigation. This review will discuss the mechanisms responsible for MMBD and therapeutic approaches currently in use and in development for the management of MMBD.

KW - Angiogenesis

KW - Bone marrow microenvironment

KW - Myeloma

KW - Myeloma bone disease

KW - Osteoblast

KW - Osteoclast

UR - http://www.scopus.com/inward/record.url?scp=84882315738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882315738&partnerID=8YFLogxK

U2 - 10.1016/j.jbo.2013.04.001

DO - 10.1016/j.jbo.2013.04.001

M3 - Article

VL - 2

SP - 59

EP - 69

JO - Journal of Bone Oncology

JF - Journal of Bone Oncology

SN - 2212-1374

IS - 2

ER -